Publications by authors named "R Colomer"
Introduction: Peripheral blood mononuclear cells (PBMCs) trafficking is regulated by chemokines, which modulate leukocyte migration toward tumors and may collaborate in the efficacy of immunotherapy. In our study, we investigated whether the CXCL12/CXCR4 axis plays a role in the efficacy of immunotherapy in non-small cell lung cancer (NSCLC) by analyzing CXCR4 expression for CXCR4 in peripheral blood (PB), and the expression of its ligand CXCL12 in tumor.
Methods: We identified PBMCs expressing CXCR4 using flow cytometry in a prospective cohort of NSCLC patients before starting anti-PD-1 immunotherapy.
Article Synopsis
- - Tumor immune microenvironment (TIME) significantly influences how prostate cancer (PC) responds to treatments and understanding mechanisms of resistance is crucial.
- - Research indicates that certain genomic changes, like microsatellite instability (MSI) and CDK12 bi-allelic loss, may increase response rates to immune therapies, but patient responses vary widely.
- - The review explores how immune cell interactions within tumors affect PC progression, how standard therapies impact immune responses, and the challenges in analyzing the immune landscape related to tumors.
Article Synopsis
- This study looked at how a medicine called nintedanib might help with breast cancer by making the environment around the tumor less stiff.
- Researchers tested this by comparing two groups of patients: one got regular treatment while the other received nintedanib with their treatment.
- They found that although overall survival rates were similar, patients with high stiffness scores (MeCo) had a higher risk of cancer returning, but taking nintedanib lowered that risk.
This revised consensus statement of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathological Anatomy (SEAP) updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer that we first published in 2018. The expert group recommends determining in early breast cancer the estrogen receptor (ER), progesterone receptor (PR), Ki-67, and Human Epidermal growth factor Receptor 2 (HER2), as well as BReast CAncer (BRCA) genes in high-risk HER2-negative breast cancer, to assist prognosis and help in indicating the therapeutic options, including hormone therapy, chemotherapy, anti-HER2 therapy, and other targeted therapies. One of the four available genetic prognostic platforms (Oncotype DX, MammaPrint, Prosigna, or EndoPredict) may be used in ER-positive patients with early breast cancer to establish a prognostic category and help decide with the patient whether adjuvant treatment may be limited to hormonal therapy.
View Article and Find Full Text PDFCancer survival is becoming more common which means that there is now a growing population of cancer survivors, in whom pain may be common. However, its prevalence has hardly been addressed systematically. We aimed to assess the prevalence and explore the pathophysiology and impact of pain on health outcomes in cancer survivors.
View Article and Find Full Text PDF